Regeneron Pharmaceuticals (NASDAQ:REGN) Director Sells 7,439 Shares of Stock

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Director Huda Zoghbi sold 7,439 shares of the firm’s stock in a transaction dated Tuesday, November 3rd. The shares were sold at an average price of $970.46, for a total transaction of $7,219,251.94. Following the completion of the sale, the director owned 1,703 shares of the company’s stock, valued at approximately $1,652,693.38. The trade was a 81.37% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN traded down $28.31 on Thursday, hitting $902.36. 1,398,293 shares of the company’s stock were exchanged, compared to its average volume of 833,634. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.35 and a quick ratio of 3.66. The firm’s 50-day moving average price is $800.69 and its two-hundred day moving average price is $741.11. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $591.52 and a fifty-two week high of $991.73. The firm has a market cap of $92.91 billion, a price-to-earnings ratio of 19.92, a P/E/G ratio of 1.45 and a beta of 0.10.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Friday, October 30th. The biopharmaceutical company reported $20.07 EPS for the quarter, beating the consensus estimate of $16.51 by $3.56. Regeneron Pharmaceuticals had a return on equity of 16.01% and a net margin of 28.51%. The business had revenue of $5.12 billion during the quarter, compared to analysts’ expectations of $4.58 billion. During the same period last year, the firm earned $11.83 EPS. The company’s quarterly revenue was up 36.3% compared to the same quarter last year. On average, research analysts expect that Regeneron Pharmaceuticals, Inc. will post 51.64 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, December 3rd. Stockholders of record on Friday, November 20th will be paid a dividend of $0.94 per share. The ex-dividend date of this dividend is Friday, November 20th. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.4%. Regeneron Pharmaceuticals’s dividend payout ratio is 8.30%.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Illinois Municipal Retirement Fund increased its position in Regeneron Pharmaceuticals by 3.9% during the 3rd quarter. Illinois Municipal Retirement Fund now owns 31,884 shares of the biopharmaceutical company’s stock worth $24,177,000 after purchasing an additional 1,209 shares in the last quarter. Lido Advisors LLC lifted its position in Regeneron Pharmaceuticals by 26.0% during the third quarter. Lido Advisors LLC now owns 14,677 shares of the biopharmaceutical company’s stock valued at $11,129,000 after buying an additional 3,030 shares in the last quarter. Cornerstone Wealth Management LLC acquired a new position in Regeneron Pharmaceuticals during the third quarter valued at approximately $254,000. Csenge Advisory Group purchased a new stake in Regeneron Pharmaceuticals during the third quarter worth approximately $237,000. Finally, Kestra Investment Management LLC grew its stake in Regeneron Pharmaceuticals by 2.4% during the third quarter. Kestra Investment Management LLC now owns 675 shares of the biopharmaceutical company’s stock worth $512,000 after buying an additional 16 shares during the period. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on REGN. Zacks Research raised Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Monday, September 28th. Bank of America raised their target price on shares of Regeneron Pharmaceuticals from $908.00 to $1,030.00 and gave the company a “buy” rating in a report on Monday. Morgan Stanley boosted their target price on shares of Regeneron Pharmaceuticals from $779.00 to $855.00 and gave the company an “equal weight” rating in a research note on Monday. Cantor Fitzgerald increased their price target on Regeneron Pharmaceuticals from $795.00 to $980.00 and gave the stock an “overweight” rating in a research note on Monday. Finally, Evercore raised their target price on shares of Regeneron Pharmaceuticals from $825.00 to $850.00 and gave the stock an “outperform” rating in a research report on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $898.97.

Key Headlines Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Regeneron advanced ALN-CIDEB into a Phase 3 study for liver disease, marking progress for its clinical pipeline. The available report did not provide further trial details. Regeneron advances ALN-CIDEB
• Positive Sentiment: The company joined the Mary Tyler Moore Vision Initiative consortium as a founding member, adding to its involvement in vision research. Regeneron joins vision initiative consortium
• Positive Sentiment: Recent coverage cited favorable earnings-estimate revisions, analyst price-target increases, and Bank of America’s addition of REGN to its Value 10 list. These follow a recent quarterly earnings and revenue beat, though much of this news predates today’s session. Analyst outlook and estimate revisions BofA adds REGN to Value 10 list
• Negative Sentiment: EVP Joseph Larosa sold 4,466 shares worth about $4.3 million, and director Christine Poon sold 7,830 shares. These disclosures may weigh on sentiment, although insider sales do not necessarily signal concerns about the business. EVP stock sale

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.